Worldwide Pharmaceuticals Contract Development & Manufacturing Industry to 2026 - Increasing Demand for Biological Therapies Presents Opportunities

DUBLIN, May 20, 2021 /PRNewswire/ -- The "Global Pharmaceuticals Contract Development & Manufacturing Market (2021-2026) by Service, End-user, Geography and the Impact of COVID-19 with Ansoff Analysis, Infogence Competitive Quadrant" report has been added to ResearchAndMarkets.com's offering.

The Global Pharmaceutical Contract Development & Manufacturing Market is estimated to be $107.2 billion 2021 and is expected to reach $152.6 billion by 2026 growing at a CAGR of 7.3%.

The Pharmaceutical Market is changing very rapidly. Emerging global markets and pricing pressures are responsible for the transformation of these companies. In such a scenario, providers to the pharmaceutical industries such as contract developers and manufacturers need to transform to sustain in the market and match the competitiveness of the marketplace. Distinguished offerings to the customers are the only way to grow the business. Those that can fill this gap by taking benefit of the transformative nature of the industry can only emerge as market leaders.

One of the reasons for the increase in the pharmaceutical contract development and manufacturing industry is the growth of developing biotech. Most of the companies are continuously involved in the development of complex drug compounds to address a specific disease. Most of the companies lack the infrastructure required for formulation, clinical, and regulatory agency submission. Commonly, the final decision for these companies is to sell to a big player in the pharma or a biotech market. A partnership with a pharmaceutical contract manufacturer can provide another viable option. By working cooperatively, an emergent biotech company, an established donor company, and a pharmaceutical contract manufacturer can move a product into the global markets.

The increasing level of mergers and acquisition activities are resulting in the consolidation of the contract service providers. The growth of the Pharmaceutical Contract Development and Manufacturing Market is driven by the increasing demand for generics across the globe. The increasing investment in pharmaceutical R&D by the companies pushes the growth of the market upwards.

The pharmaceutical contract development and manufacturing market are hindered by the inadequate capacity utilization of manufacturing facilities by the companies. The poor-capacity utilization of the manufacturing unit is caused due to the inefficiency of different sub-processes involved in the production process, which further results in low production. The low production is responsible for decreased revenue, thus affecting the overall pharmaceutical contract development and manufacturing market.

Dynamic changes witnessed in this sector, coupled with severe pressure over the profit margins, are anticipated to restrain growth. Stringent and complex Government regulatory requirements are also attributive to slow progress.

Market Dynamics

Drivers

• Growing Demand for Generics
• Increasing Investments in Pharmaceutical R&D
• Investments in Advanced Manufacturing Technologies by CDMOS

Restraints

• The increasing lead time and logistics costs
• Strict Governmental Regulations Needed for the Approval of drugs

Opportunities

• Increasing Demand for Biological therapies
• Growing Focus on Specialty Medicines
• Growth in the Nuclear Medicine Sector
• Increasing Demand for Cell and Gene therapies

Challenges

• Managing Costs and Astutely Investing in Technology

Company Profiles

Some of the companies covered in this report are Thermo Fisher Scientific Inc., Catalent, Inc., Lonza Group Ltd, Recipharm AB, Vetter Pharma International GmbH, Famar Health Care Services, Abbvie Inc., Aenova Group, Consort Medical Plc, and others.

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

• Lions: Represents companies with a strong foothold in the market, with the highest market share, large investments in technologies, new products.
• Bulls: Companies that are medium in size competing with their USPs, growing companies with proven market share.
• Rabbits: Small companies but growing rapidly, constantly improving their offerings in the market
• Tortoise: Companies which are slow in growth, having a long legacy, and stable or negative in performance

Why buy this report?

• The report offers a comprehensive evaluation of the Global Pharmaceutical Contract Development & Manufacturing Market.
• The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
• The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
• The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
• The report also contains the competitive analysis using Competitive Quadrant, the analyst's proprietary competitive positioning tool.

Report Highlights:

• A complete analysis of the market including parent industry
• Important market dynamics and trends
• Market segmentation
• Historical, current, and projected size of the market based on value and volume
• Market shares and strategies of key players
• Recommendations to companies for strengthening their foothold in the market

Key Topics Covered:

1. Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders

2. Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study

3. Executive Summary

4. Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Trends

5. Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis

6. Global Pharmaceutical Contract Development & Manufacturing Market, By Service
6.1 Pharmaceutical Manufacturing Services
6.1.1 Pharmaceutical API Manufacturing Services
6.1.2 Pharmaceutical FDF Manufacturing Services
6.1.3 Parenteral/Injectable Manufacturing Services
6.1.4 Tablet Manufacturing Services
6.1.5 Capsule Manufacturing Services
6.1.6 Oral Liquid Manufacturing Services
6.1.7 Other Formulations
6.2 Drug Development Services
6.3 Biologics Manufacturing Services
6.3.1 Biologics API Manufacturing Services
6.3.2 Biologics FDF Manufacturing Services

7. Global Pharmaceutical Contract Development & Manufacturing Market, By End User
7.1 Big Pharma
7.2 Small & Mid-Size Pharma
7.3 Generic Pharmaceutical Companies
7.4 Other End Users

8. Pharmacy Automation Systems Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 South America
8.3.1 Brazil
8.3.2 Argentina
8.4 Europe
8.4.1 UK
8.4.2 France
8.4.3 Germany
8.4.4 Italy
8.4.5 Rest of Europe
8.5 Asia-Pacific
8.5.1 China
8.5.2 Japan
8.5.3 India
8.5.4 Australia
8.5.5 Rest of APAC
8.6 Middle East and Africa

9. Competitive Landscape
9.1 Infogence Competitive Quadrant
9.2 Market Share Analysis
9.3 Competitive Scenario
9.3.1 Mergers & Acquisitions
9.3.2 Agreements, Collaborations, & Partnerships
9.3.3 New Product Launches & Enhancements
9.3.4 Investments & Fundings

10. Company Profiles
10.1 Thermo Fisher Scientific Inc.
10.2 Catalent, Inc.
10.3 Lonza Group Ltd
10.4 Recipharm AB
10.5 Veter Pharma International GmbH
10.6 Famar Healthcare Services
10.7 Abbvie Inc.
10.8 Aenova Group
10.9 Almac Group
10.10 Siegfried Holding AG
10.11 Evonik Industries AG
10.12 Boehringer Ingelheim International GmbH
10.13 Jubilant Life Sciences Ltd.
10.14 Patheon Inc.
10.15 Pfizer CentreSource
10.16 CMIC Holdings Co. Ltd
10.17 Syneos Health Inc.
10.18 LSK Global Pharma Service Co Ltd.
10.19 PAREXEL International Corporation
10.20 PRA Health Sciences Inc.
10.21 Samsung Bioepis Co. Ltd.
10.22 Sagimet Biosciences (3V Biosciences Inc.)
10.23 WuXi AppTec Inc
10.24 Quanticate Ltd.
10.25 SGS SA (SGS Life Sciences)

11. Appendix
11.1 Questionnaire

For more information about this report visit https://www.researchandmarkets.com/r/x8j5oi

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com